gonadotropin-releasing hormone agonist + gonadotropin-releasing hormone antagonist

The combination of a **gonadotropin-releasing hormone agonist (GnRH agonist)** and a **gonadotropin-releasing hormone antagonist (GnRH antagonist)** is an experimental pharmacological strategy intended to harness the rapid, potent suppression of the hypothalamic-pituitary-gonadal axis. This combination aims to provide the immediate downregulation of gonadotropin and sex steroid levels achieved by antagonists (thus avoiding the initial "flare" typically induced by agonists) while maintaining sustained suppression from the agonist. This regimen has been primarily investigated in the context of fertility preservation and protection from chemotherapy-induced gonadotoxicity, notably in animal models and preliminary human studies. Mechanistically, the agonist initially stimulates gonadotropin release before leading to receptor desensitization and suppression, while the antagonist competitively and immediately inhibits GnRH receptor signaling, blocking gonadotropin release from the pituitary[1]. The combination abolishes the initial gonadotropin (e.g., LH, FSH) flare associated with the agonist and achieves a rapid, durable suppression of gonadal function, with potential applications in oncology, reproductive endocrinology, and mitigation of hormone-driven tumor progression[1].

Other names

gonadotropin-releasing hormone agonist + gonadotropin-releasing hormone antagonistGnRH agonist + GnRH antagonistLHRH agonist + LHRH antagonist